Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor #MMPMID30223868
Rodriguez-Munoz M; Onetti Y; Cortes-Montero E; Garzon J; Sanchez-Blazquez P
Mol Brain 2018[Sep]; 11 (1): 51 PMID30223868show ga
Cannabidiol (CBD), the major non-psychotomimetic compound present in the Cannabis sativa plant, exhibits therapeutic potential for various human diseases, including chronic neurodegenerative diseases, such as Alzheimer's and Parkinson's, ischemic stroke, epilepsy and other convulsive syndromes, neuropsychiatric disorders, neuropathic allodynia and certain types of cancer. CBD does not bind directly to endocannabinoid receptors 1 and 2, and despite research efforts, its specific targets remain to be fully identified. Notably, sigma 1 receptor (sigma1R) antagonists inhibit glutamate N-methyl-D-aspartate acid receptor (NMDAR) activity and display positive effects on most of the aforesaid diseases. Thus, we investigated the effects of CBD on three animal models in which NMDAR overactivity plays a critical role: opioid analgesia attenuation, NMDA-induced convulsive syndrome and ischemic stroke. In an in vitro assay, CBD disrupted the regulatory association of sigma1R with the NR1 subunit of NMDAR, an effect shared by sigma1R antagonists, such as BD1063 and progesterone, and prevented by sigma1R agonists, such as 4-IBP, PPCC and PRE084. The in vivo administration of CBD or BD1063 enhanced morphine-evoked supraspinal antinociception, alleviated NMDA-induced convulsive syndrome, and reduced the infarct size caused by permanent unilateral middle cerebral artery occlusion. These positive effects of CBD were reduced by the sigma1R agonists PRE084 and PPCC, and absent in sigma1R(-/-) mice. Thus, CBD displays antagonist-like activity toward sigma1R to reduce the negative effects of NMDAR overactivity in the abovementioned experimental situations.
free
free
free
Mol+Brain 2018 ; 11 (1): 51
